Physician profile
Derek Justice Jay
NPI 1427819721
$733.41
in general payments reported to CMS, 2019-2025
13 companies · $637 in 2025
The $637 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $96.63 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $733.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $180.62 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $151.57 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $90.66 | 2025 | |
| Novo Nordisk INC | $53.62 | 2024-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $53.50 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Abbott Laboratories | $43.37 | 2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $35.77 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lilly USA, LLC | $33.94 | 2024-2025 | Mounjaro, Zepbound |
| Xeris Pharmaceuticals, INC. | $24.90 | 2025 | Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.07 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $16.52 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $15.40 | 2024 | Eliquis |
| Amgen INC. | $13.47 | 2025 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Jay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.